Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations

J Rheumatol. 1996 May;23(5):850-5.


Objective: To evaluate the relationship between quinolinic acid, a neuroactive metabolite of L-tryptophan, and neuropsychiatric manifestations of systemic lupus erythematosus (SLE).

Methods: Forty specimens of cerebrospinal fluid (CSF) were obtained from 39 patients with SLE who were evaluated for 40 episodes of neuropsychiatric dysfunction. The diagnosis of the neuropsychiatric dysfunction was determined clinically. CSF and serum specimens were analyzed for levels of quinolinic acid without knowledge of the clinical diagnosis.

Results: Neuropsychiatric dysfunction attributed to SLE (NPSLE) was confirmed in 30 patient-episodes (Group 1), whereas in the other 10 (Group 2) other etiologies were felt to explain their CNS dysfunction. The median levels of CSF quinolinic acid for Group 1 (232.5 nmol/l) were significantly higher than those for Group 2 (median 38.2 nmol/l) (p < 0.014). CSF and serum quinolinic acid levels correlated significantly (p < 0.003) but there was not correlation between CSF quinolinic acid and CSF protein concentrations or white blood cell counts.

Conclusion: We conclude that elevated quinolinic acid levels in the CSF and serum may be associated with NPSLE and could possibly play a role in its pathogenesis.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Brain Diseases / diagnosis
  • Brain Diseases / etiology*
  • Brain Diseases / metabolism
  • Demography
  • Electroencephalography
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / cerebrospinal fluid
  • Lupus Erythematosus, Systemic / complications*
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Quinolinic Acid / analysis*
  • Tomography, X-Ray Computed
  • Tryptophan / metabolism


  • Tryptophan
  • Quinolinic Acid